PROMOMED prepared the launch of production of effective drug for COVID-19 at the BIOKHIMIK JSC production site
Promomed 03 May 2020
The company has made a breakthrough – its scientists and specialists have developed and recreated the production technology of favipiravir. The drug blocks the reproduction of the virus in human cells, thereby preventing the spread of infection in the body.
«Favipiravir is effective against RNA viruses including COVID-19 coronavirus,» Dmitry Zemskov, Executive Director of Biokhimik JSC, comments on the achievement of the enterprise.
This drug was developed in Japan to treat atypical fevers, in particular Ebola, as well as to control hard-to-treat forms of influenza. The peculiarity of the drug is that viruses resistant to it practically do not exist. The drug remains effective throughout the epidemic, which allows it to be called a rescue drug. At the moment, extensive clinical trials of this drug are underway around the world, but we can already rely on the data we receive from abroad. Favipiravir has been widely used in the treatment of COVID-19 coronavirus infection in China. Experts note its high efficacy, which significantly reduces the time of COVID-19 infection in the body, to almost 4 days; provides good preservation of lung tissue, which is confirmed by numerous studies, and has very few side effects.
«Favipiravir is effective against RNA viruses including COVID-19 coronavirus,» Dmitry Zemskov, Executive Director of Biokhimik JSC, comments on the achievement of the enterprise.
This drug was developed in Japan to treat atypical fevers, in particular Ebola, as well as to control hard-to-treat forms of influenza. The peculiarity of the drug is that viruses resistant to it practically do not exist. The drug remains effective throughout the epidemic, which allows it to be called a rescue drug. At the moment, extensive clinical trials of this drug are underway around the world, but we can already rely on the data we receive from abroad. Favipiravir has been widely used in the treatment of COVID-19 coronavirus infection in China. Experts note its high efficacy, which significantly reduces the time of COVID-19 infection in the body, to almost 4 days; provides good preservation of lung tissue, which is confirmed by numerous studies, and has very few side effects.
PROMOMED actively developing its own antiviral program, acting in accordance with Government Decree No. 441 of 03.04.2020, applied to the Ministry of Health of the Russian Federation with a request to approve favipiravir manufactured by PROMOMED. Today, the company is ready for production of both the finished dosage form and for the favipiravir substance. «We really hope that in June and July 2020 we will be able to provide all medical and preventive institutions of our country with this drug,» says Dmitry Zemskov. «Our drug containing favipiravir as active ingredient will have a trade name Areplivir.»
PROMOMED is at the forefront of the fight against coronavirus infection from the very beginning. We produce 19 antibacterial agents at our BIOKHIMIK JSC production site, which are approved by the Ministry of Health in the COVID-19 treatment guidelines.
PROMOMED is at the forefront of the fight against coronavirus infection from the very beginning. We produce 19 antibacterial agents at our BIOKHIMIK JSC production site, which are approved by the Ministry of Health in the COVID-19 treatment guidelines.
